Dissection of the anti-\textit{Candida albicans} mannan immune response using synthetic oligomannosides reveals unique properties of $\beta$-1,2 mannotriose protective epitopes

Boualem Sendid$^{1,2,}$*, Karine Lecointe$^1$, Mayeul Collot$^2$, Pierre-Marie Danzé$^3$, Sébastien Damiens$^4$, Anne-Sophie Drucbert$^3$, Chantal Fradin$^4$, Jean-Pierre Vilcot$^3$, Frédéric Grenouillet$^6$, Faustine Dubar$^1$, Jérôme de Ruyck$^1$, Samir Jawhara$^1$, Jean-Maurice Mallet$^2$ & Daniel Poulain$^{1,13}$

\textit{Candida albicans} mannan consists of a large repertoire of oligomannosides with different types of mannose linkages and chain lengths, which act as individual epitopes with more or less overlapping antibody specificities. Although anti-\textit{C. albicans} mannan antibody levels are monitored for diagnostic purposes nothing is known about the qualitative distribution of these antibodies in terms of epitope specificity. We addressed this question using a bank of previously synthesized biotin sulfone tagged oligomannosides (BSTOs) of $\alpha$ and $\beta$ anomery complemented with a synthetic $\beta$-mannotriose described as a protective epitope. The reactivity of these BSTOs was analyzed with IgM isotype monoclonal antibodies (MAbs) of known specificity, polyclonal sera from patients colonized or infected with \textit{C. albicans}, and mannos binding lectin (MBL). Surface plasmon resonance (SPR) and multiple analyte profiling (MAP) were used. Both methods confirmed the usual reactivity of MAbs against either $\alpha$ or $\beta$ linkages, excepted for MAb B6.1 (protective epitope) reacting with $\beta$-Man whereas the corresponding BSTO reacted with anti-$\alpha$-Man. These results were confirmed in western blots with native \textit{C. albicans} antigens. Using patients' sera in MAP, a significant correlation was observed between the detection of anti-mannan antibodies recognizing $\beta$- and $\alpha$-Man epitopes and detection of antibodies against $\beta$-linked mannotriose suggesting that this epitope also reacts with human polyclonal antibodies of both specificities. By contrast, the reactivity of human sera with other $\alpha$- and $\beta$-linked BSTOs clearly differed according to their colonized or infected status. In these cases, the establishment of an $\alpha/\beta$ ratio was extremely discriminant. Finally SPR with MBL, an important lectin of innate immunity to \textit{C. albicans}, classically known to interact with $\alpha$-mannose, also interacted in an unexpected way with the protective epitope. These cumulative data suggest that structure/activity investigations of the finely tuned \textit{C. albicans} anti-mannose immune response are worthwhile to increase our basic knowledge and for translation in medicine.

Many studies have demonstrated that molecules essential for normal cell physiology are usually glycosylated and variations in their glycosylation patterns often induce changes in their function. These changes have been reported in both prokaryotic and eukaryotic organisms$^1$. In fungi, oligosaccharides are important molecules playing a crucial role in fungal cell–cell communication and host–pathogen interactions involving innate immunity.

$^1$INSERM U1285, Univ. Lille, CHU de Lille, UMR CNRS 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, 59000 Lille, France. $^2$École Normale Supérieure, Département de Chimie, Laboratoire des Biomolécules, UMR CNRS 7203, 24 rue Lhomond, 75005 Paris, France. $^3$Institut de Biochimie, CHU de Lille, 59037 Lille Cedex, France. $^4$Univ. Lille, INSERM, CHU Lille, Pasteur Institute of Lille, U1167 - RID-AGE, 59000 Lille, France. $^5$Institut D'Électronique de Microélectronique et de Nanotechnologie (IEMN), UMR 8520, Université de Lille, Villeneuve d'Ascq, France. $^6$Department of Parasitology-Mycology, University Hospital, Besançon, France. $^*$email: boualem.sendid@univ-lille.fr; daniel.poulain@univ-lille.fr
receptors. Conjugated to proteins or lipids, oligosaccharides elicit strong antibody responses as a result of fungal tissue invasion. From a more general point of view, as they have a high level of specificity, anti-oligosaccharide antibodies are widely used as a tool for blood grouping, control of vaccination status, or serotyping of viral and bacterial agents.

The C. albicans cell wall is a multilayered structure composed mainly of sugars (> 80%) and to a lesser extent proteins and lipids. The surface is covered by phosphopeptidomannan (commonly named mannan), a high molecular weight matrical component, expressing a large repertoire of α- and β-oligomannosides. PPM is interwoven with numerous mannanproteins (MPs) emerging at the cell surface and covalently bound to the inner layer composed of glucans. These mannanproteins are distributed in GPI anchor or PIR proteins depending on their type of linkage to glucans. Of note, these MPs display the same oligomannose repertoire as PPM. The cell wall surface is also covered by a glycolipid with β-mannose epitopes known as phospholipomannan (PLM). The intermediate layer of the cell wall is composed of a polysaccharide polymer backbone consisting of β-glucans (both β-1,3, and β-1,6-D-glucopyranosyls) while a chitin matrix participates in the hydrophobic layer of the cell membrane. From an immunological point of view, mannans and β-glucans are differently recognized by host pattern recognition receptors (PRRs). β-1,3-glucans are recognized by dectin-1, α-mannan is recognized by the mannose receptor, dectin-2, DC-SIGN, mannose-binding lectin (MBL), and langerin, whereas β-mannans are specifically recognized by galectin-3.

Anti-glycan/oligosaccharide antibodies are also used as biomarkers for the diagnosis of human invasive or allergic fungal diseases. Anti-oligosaccharide antibody specificity is conferred by the nature of the constitutive sugar sequences, the type of linkage and the length of the oligosaccharide chain. For immunoassays, these carbohydrate antigens need to be immobilized on the surface of microtiter plates or magnetic microspheres, which represents a challenging task. This pitfall has been overcome by using synthetic oligosaccharides, which can be prepared with a versatile anchor group. Biotin is the most widely used of these as it selectively binds to avidin and are successfully used in immunoassays.

For experimental purposes, surface plasmon resonance (SPR) has been used to decipher the interactions between oligosaccharidases and proteins or peptides. Such investigations were performed to characterize lectin-microbial interactions. MBL is a multimer of polypeptide chains 32 kDa in size. Three polypeptide chains make up a triple helix with a collagenous region, which is the basic circulating subunit of MBL. In serum, MBL is composed of oligomers of subunits from dimers to hexamers, which are effector forms of the lectins for glycan or pathogen interactions. MBL interacts with terminal-D-mannose residues, L-fucose, and GlcNAc but also with bacteria, virus, molds, yeasts, and parasites. It is known that MBL can recognize C. albicans mannose receptor, dectin-2, DC-SIGN, mannose-binding lectin (MBL), and langerin, whereas β-mannans are specifically recognized by galectin-3.

The main objectives of the present study were to use synthetic oligosaccharides to carry out epitope mapping of the main monoclonal antibodies (MAbs) directed against the cell wall of C. albicans, to identify the oligomannoside epitopes recognized by MBL through SPR, and to dissect the anti-mannan antibody response in the serum of patients with invasive candidiasis using multi-analyte profiling (MAP) technology. To reach these objectives a bank of previously synthesized biotin sulfone tagged oligomannosides (BSTOs) of α and β anomery was complemented with the synthetic β-mannotriose described as a protective epitope. This revealed unexpected results regarding previous paradigms of C. albicans mannose epitope recognition.

**Results**

**MAP analysis of BSTO reactivity with anti-carbohydrate MAbs.** Five BSTO epitopes were individually coupled to different batches of microsphere beads and tested with the panel of anti-C. albicans MAbs. As shown in Fig. 1, the anti-galactofuran MAb (EB-A2) did not generate any signal with any of the mannose residues presented as BSTOs. As expected, MAb 5B2 bound selectively to members of the β-mannose family (~ 600 RU) and 4β-Man (~ 800 RU) (Fig. 2b, e). These results can also be observed for 3β-Man in a less important
manner (~ 300 RU) (Fig. 2c left panel). There was no interaction with 2α-Man and 4α-Man (Fig. 2a, 3d). MAb B6.1 showed strong binding to 3β-Man and 4β-Man. The absence of response with EB-A2 injections used as a control on each sensorgram confirms the specificity of the binding with the other antibodies. Saturability of the interactions was not performed because of the IgM nature of the antibodies which have 10 binding sites per molecule.

Data obtained by SPR confirmed those observed with MAP in terms of differential binding conditioned by anomery and oligomannoside chain length. The only discrepancy concerned the amplitude of signals between the two technologies. Overall, the MAP and SPR results confirmed the reactivity of MAb EB-CA1 with 3β-Man as the first real exception observed so far to the specificity of anti-mannoside antibodies conferred by their anomeric configuration. It is not the specificity of the “protective” antibody that is questionable (B6.1), but the ability of the “protective epitope” to react with both anti-β-mannoside antibodies and anti-α-mannoside antibodies. We then aimed to confirm these data using native antigens from *C. albicans* known to express the protective epitope.

**Western blot analysis of EB-CA1 and B6.1 MAb reactivities against mannoglycoconjugates from *C. albicans* serotype A and B strains.** In order to confirm the reactivity of the 3β-Man “protective epitope” with an anti-α-Man antibody western blot experiments were performed involving an extensively characterized molecule, PLM. PLM is a member of the manno-inositol phosphoceramide (MIPC) family with an apparent rMW of 14–18 kDa in western blots, and with a polysaccharide moiety composed of long linear chains of β-Man in *C. albicans* serotype A strains (Fig. 3 insert, lane BWP17). Later, it was discovered that this cell wall surface molecule differed in *C. albicans* serotype B strains with a rMW of approximately 7 kDa (Fig. 3 insert Lane NIH B). Structural studies established that this shift in rMW was related to a truncated glycan moiety that corresponded to a trimannoside. This truncation was reproduced by inactivation of β-mannosyl transferase 6 (*BMT6*), responsible for the addition of the third β-mannose in serotype A strains. Natural and genetically constructed variants of PLM therefore seemed particularly well adapted to confirm the unexpected reactivity of the protective epitope with MAb EB-CA1 (Fig. 3). When these extracts were probed with B6.1 and EB-CA1 MAbs, reactivity was observed with numerous of bands of rMW > 40 kDa in accordance with previous data that showed that both epitopes are distributed over a large number of mannoproteins that display a polydisperse character in the gel as a function of the increased molecular weight and increased size of their reactive polysaccharide moiety. Western blots performed with control MAb EB-A2 did not show any reactivity. Among the *C. albicans* glycoconjugates, we focused our analysis on PLM (Fig. 3, arrow). PLM of *C. albicans* serotype A VW32 and BWP17 strains had no reactivity with MAb B6.1 in contrast to *C. albicans* serotype B NIH B-792 and *C. albicans* serotype A *bmt6Δ* strain where deletion of both alleles of *BMT6* resulted in a truncated PLM with an accumula-
tion of 3β-Man. Interestingly, MAb EB-CA1, specific for 4α-Man, displayed the same reactivity as MAb B6.1 with 3β-Man. Additional information concerning the technical procedure of WB used for generating Fig. 3 is available in the supplementary information section with specific references.

Analysis of human antibody response with anti-mannan ELISA test and MAP involving different BSTOs for their differential ability to discriminate between controls, colonized, and Candida-infected patients. Systemic Candida infection is generally associated with a sharp rise in anti-C. albicans mannan antibodies leading to titers rarely encountered in non-infected patients. In parallel, mannanemia, (i.e. the release of mannan into patients’ sera resulting from host tissue invasion by Candida) may also be detected. On this basis, it has been proposed to combine the detection of anti-C. albicans mannan antibodies and mannanemia as a diagnostic strategy to compensate for the poor sensitivity of blood cultures.

The results of the anti-C. albicans mannan antibody tests are plotted on Fig. 4a for each of the 181 sera taken from 30 infected intensive care unit (ICU) patients as well as the associated values for mannanemia. When considering the values for the same tests in non-infected ICU patients, a larger proportion than healthy controls also had high anti-mannan antibody titers in relation to the heavy colonization observed for most patients during hospitalization. A similar distribution was observed when considering the reactivity of human sera against 3β-Man (Fig. 4b).

Although different results could have been expected using 3β-Man as a single epitope, the results observed with infected patients’ sera correlated with those obtained with mannan (Fig. 4e). When performing the same analysis with other BSTOs the results were heterogeneous by comparison to anti-mannan reactivity. Examples
are given for the distribution of 2α-Man and 2β-Man in Fig. 4c, d, respectively, and the Spearman's rank correlation coefficients with mannan reactivity are shown as a function of the BSTO in Fig. 4f. Altogether these findings revealed the property of 3β-Man to mimic the mannan repertoire of β- and α-mannoside epitopes, and confirms its unique ability to bind both anti-β and anti-α mannose antibodies in human sera, as shown previously with MAbs in MAP and SPR.

We then investigated whether other BSTOs would discriminate infected patients from other ICU patients (Fig. 5). Surprisingly, when using 2α-Man, reactivity decreased from controls to colonized and infected patients (Fig. 5a) (i.e. the converse of what would have been expected for identifying infected patients). By contrast, 2β-Man reactivity increased markedly in infected patients (Fig. 5b). Although these results were discriminatory per se we decided to determine the α/β reactivity ratio. As shown in Fig. 5c, more discrimination was observed between patients in relation to *C. albicans* saprophyte/pathogen transition.

The results of the statistical analysis of the ability of antigens to discriminate the different study groups are shown in Fig. 5d. The *p* values are reported for each comparison. 3β-Man and 2β-Man/2α-Man ratio provided the best discrimination whatever the categories compared. However major differences were observed depending on the groups under comparison with some antigens even giving non-significant results. This reveals the complex framework of *C. albicans* mannoserepertoire recognition depending on the patient's status.

**SPR analysis of BSTO-MBL interaction.** To further establish the interaction between oligomannosides and recombinant (r)MBL, SPR experiments were carried out using BIAcore 3000. An example of a typical sensogram of the interaction is shown in Fig. 6a with 3β-Man. To characterize how the oligomannose anomer and degree of polymerization may influence binding to rMBL, the different oligomannosides were screened at 0, 0.25, 0.5, 1, and 2 mM (Fig. 6b). Although the interaction was characterized by low signals (<100 RU), SPR sensograms clearly demonstrated differential interactions of BSTOs with rMBL.

As expected, for one MBL ligand already identified, specific binding occurred with 2α-Man. 4α-Man, which presents the same structure at its terminal non-reducing end, also displayed strong binding. Among the β-1,2
linked oligomannosides, 2β-Man displayed very low affinity, and although the 4β-Man signal was better, it was still weak and was not saturable even at high concentrations. Interestingly, the affinity curves for 3β-Man and 4α-Man were almost superimposable. These results were confirmed by regression curves displaying a correlation coefficient of > 0.9 and similar slopes (data not shown). Thus, these results obtained with a lectin of innate immunity sensing *C. albicans* PAMPs confirm the unique behavior of the 3β-Man “protective epitope” among the β-Man series observed with monoclonal and polyclonal antibodies.

**Discussion**

The cell wall of *C. albicans* is a complex stratified and dynamic structure responsible for cell integrity and plays a pivotal role in host-yeast interactions. The cell wall is involved in adhesion, invasion, and is the target of innate and adaptive immune responses.

Among the cell wall polysaccharides, mannan is widely recognized to have an immunomodulatory effect. Its structure has been well established by an impressive series of structural and serological studies from Suzuki’s group. These authors established that *C. albicans* mannan is similar to the mannan of the closely related species *S. cerevisiae*, extensively studied as a model of glycosylation, with a comb-shaped structure composed of α-1,2, α-1,3, and α-1,6 mannose residues, but that *C. albicans*, *C. tropicalis* and *C. glabrata*, now reported as responsible for 90% of human *Candida* infections, also have the ability to synthesize β1,2 mannose.

Simultaneously, at a time when yeast species identification was a lengthy procedure, Fukazawa’s group developed an efficient *Candida* species identification kit (*Candida* Check; Iatron Laboratories, Tokyo, Japan). Cross-absorbed polyclonal rabbit antibodies were used for the identification of the main pathogenic *Candida* species by agglutination. The relevant antigen has been characterized as PPM and a series of seminal works about structure/activity relationships involving inhibition of agglutination together with nuclear magnetic resonance (NMR) and gas chromatography–mass spectrometry provided evidence that the antigenic determinants recognized by rabbit antisera are based on anomer of linkages (α-1,2, α-1,3, α-1,6, and β-1,2), and the degree of polymerization of mannose residues.

![Figure 4](https://www.nature.com/scientificreports/) Reactivity of human sera against *C. albicans* mannan (a) as detected by ELISA (Platelia *Candida* Ab test), and against BST-3β-Man (b), as detected by multianalyte profiling (MAP) analysis. Human sera consisted of sera from healthy controls (blood donors presenting no disease), and ICU patients either not-infected or infected with *C. albicans*. Anti-*C. albicans* mannan antibody response is shown for infected patients according to antigenemia status (negative: open symbols; positive: closed symbols) (b). The correlation between anti-mannan and 2α-Man, 2β-Man, 3β-Man antibodies is shown in (c, d, e) respectively. The values of Spearman rank correlation coefficients for the different BSTOs are given in f.
With the advent of hybridoma technology a relatively large number of anti-\(C.\) \textit{albicans} MAbs have been produced which react against \(C.\) \textit{albicans} mannan/mannoproteins. Elucidation of their epitopes confirmed that they reacted with either anti-\(\alpha\)-Man or anti-\(\beta\)-Man antibodies fitting the Iatron serological classification. Some of these MAbs were included in this study together with their BSTO epitopes. Due to interest in the protective effect of MAb B6.1 its epitope was specially constructed as a BSTO for this study.

In the present study, the specificity of these MAbs and polyclonal antibodies (human sera collected during \(Candida\) infection) was dissected using BSTOs in a qualitative and quantitative manner by SPR and MAP technology. We confirmed the specificity of 5B2 for 2\(\beta\)-Man, B6.1 for 3\(\beta\)-Man, and EB-CA1 for 4\(\alpha\)-Man. Unexpectedly, we observed that EB-CA1 also reacted with the 3\(\beta\)-Man epitope, which therefore represents the first exception to the dichotomous reactivity of mannan epitopes with either anti-\(\alpha\)-Man or anti-\(\beta\)-Man antibodies established through a large number of studies. This surprising observation, obtained by MAP and SPR, was confirmed by more conventional western blot analysis using \(C.\) \textit{albicans} serotype B PLM and a serotype A deleted strain as both structurally defined antigens expressing the 3\(\beta\)-Man epitope. Studies by Cutler et al. emphasized the protective role of the humoral response directed against this epitope in both systemic and mucosal models of \(Candida\) infection. A subsequent study showed that a monoclonal IgG3, called MAb C3.1, obtained from rabbits immunized with a liposome-mannan vaccine had the same specificity for \(\beta\)-mannotriose as MAb B6.1. Moreover, MAb C3.1 enhanced the resistance of mice to disseminated candidiasis. Lipinski et al. developed a vaccine with 3\(\beta\)-Man and showed that it induced a strong secondary antibody response in rabbits. In addition, 3\(\beta\)-Man vaccination resulted in a reduction of the fungal burden in tissues of immunocompromised rabbits after challenge with live fungal cells. Another study combining NMR, chemical mapping, and computer simulation showed the importance of 3\(\beta\)-Man as the optimal oligosaccharide for the development of a vaccine against \(C.\) \textit{albicans}. In this study, importance was given to the anomery of linkage of the mannose at the reducing end, which is the case in our study for both the synthetic 3\(\beta\)-Man BSTO and the native 3\(\beta\)-Man-IPC from serotype B PLM. Despite experimental findings concerning the protection obtained with 3\(\beta\)-Man no translation was made in the analysis of the human response looking for protective antibodies targeting mannan epitopes. When BSTOs were used to dissect patient responses against individual epitopes in healthy individuals, colonized, or infected patients variable discrimination could be observed between these groups. For example, the 2\(\alpha\)-Man response was higher in healthy controls than in patients. Conversely, 2\(\beta\)-Man antibodies were higher in infected patients, therefore representing a better diagnostic tool which was increased further by establishing the 2\(\beta\)-Man/2\(\alpha\)-Man ratio. These preliminary findings revealing the complex framework of \(C.\) \textit{albicans} mannose repertoire recognition depending on patient status may have interesting clinical applications in terms of diagnosis and prediction of outcome. They certainly deserve further larger prospective studies combining MAP analysis and bioinformatic
algorithms for the survey of hospitalized at-risk patients, particularly given that a recent study showed that patients infected with *Candida* strains displaying high levels of β1,2-mannosyl residues have a poor prognosis. With regard to 3β-Man, the significance of this response against a protective epitope cannot be evaluated in the absence of information on patient outcome. However, it had diagnostic value for discriminating colonized from infected patients. This property was shared with mannan as reflected by the Spearman correlation coefficient among the BSTOs. Thus, in coherence with results obtained with MAbs these findings revealed the property of 3β-Man to mimic the mannan repertoire of β- and α-mannoside epitopes.

MBL is a collectin with a molecular weight of 32 kDa, produced mainly by hepatocytes, that circulates in multimeric form with a predominance of the quaternary structure. MBL forms a complex with three MBL-associated serine proteases. MBL activates the lectin complement pathway after recognition of microorganisms through the carbohydrate-recognition domain. In vitro experiments using MBL purified from serum showed an interaction with the GlcNAc pentamer that activated the complement pathway. This interaction could be inhibited by mannone and N-acetylglucosamine. The carbohydrate-recognition domain of MBL senses polysaccharide patterns such as D-mannose, L-fucose, and GlcNAc on several clinically relevant pathogens including *C. albicans*. Lillegard et al. showed that depending on the growth conditions, *C. albicans* cells could fail to bind to MBL even though its cell wall contains mannone residues. They also reported variable patterns of MBL binding to yeast cells that are consistent with patterns of binding of anti-mannan MAbs to *C. albicans*. Epitopes recognized by some mannone specific MAbs are diffusely and continuously expressed on the surface of yeast cells (e.g. MAb EB-CA1 2α-Man). In contrast, epitopes recognized by other MAbs are expressed as discontinuous patchy patterns (e.g. Mab B6.1 3β-Man). It has been shown that the expression pattern of the ligand recognized by MBL is most similar to the expression of epitopes recognized by MAb B6.1.
We cannot currently explain why the B6.1 3β-Man epitope, which drew attention as a protective epitope, has the unique ability to be recognized by MAb EB-CA1 and MBL, molecules known to interact with mannose residues linked in α anomery. However, this dichotomy suggests that such an epitope could be involved in the recognition of yeasts by soluble and membrane receptors, stimulation of the adaptive immune response, and immunomodulation of mucosal and systemic defenses.

Our study suggests that an accumulation of basic and clinical information from the dissection of the anti-mannose immune response is worthwhile for a better understanding of Candida pathogenesis and better patient care through the development of vaccines.

**Materials and methods**

All methods were carried out in accordance with relevant guidelines and regulations.

**Monoclonal antibodies and antigens.** IgM isotype MAbs were selected according to their specificity. MAb EB-CA1, a rat IgM (Bio-Rad Laboratories, France), reacts with an α-(1,2)-mannopentaose as the minimal epitope. MAb 5B2, a rat-mouse hybrid IgM, reacts with β-(1,2)-mannosides with a mannobiose as the minimal epitope. MAb B6.1, a mouse IgM, has been described as specific for a β-(1,2)-mannotriose. MAb EB-A2 (Bio-Rad), reacting with a galactofuranose epitope, was used as the control. Tables 1 and 2 show the MAbs and antigens used in the study.

**Human sera.** Human antibodies against BSTOs were characterized in sera taken from three groups of individuals: (1) The first group represents 51 control sera collected from 51 blood donors presenting no disease; (2) The second group consisted of sera collected from 30 ICU patients with systemic *C. albicans* infection, proven by the isolation of *C. albicans* from blood cultures. In this group, sera were taken during the period of serological monitoring from 68 days before to 67 days after *C. albicans* was isolated from the blood; 181 sera were obtained (mean of 6.03 sera per patient); (3) The third group represents 119 sera from 30 patients hospitalized in ICU ward in Besançon University Hospital where colonization by *C. albicans* is followed bi-weekly in order to establish the colonization index (CCI). The 30 patients had been hospitalized for >10 days (mean duration 22 days, maximum 73 days). At admission, all had a corrected colonization index (CCI) of <0.25. Eight patients were constantly negative for Candida colonization, 22 had a CCI ≤ 0.4, and five evolved towards a CCI of >0.4. A total of 450 mycological samples were examined and the rates of positive isolation of Candida were: oropharynx 61%, gastric 30%, tracheal 22%, rectum 17%, and urine 6%. These colonized patients did not have firm clinical evidence of Candida infection.

**Ethics statement.** All sera used in this study were obtained from patients monitored at Lille University Hospital. No additional sampling was necessary. As sera were taken from a registered biological collection,
Patient consent was not required according to French law. Agreement for the establishment of a biological collection of invasive fungal infection samples was obtained from the French Ministry of Education and Research under reference DC2008-642. Institutional review board approval was given by the Comité de Protection des Personnes Nord-Ouest IV, the ethical committee of our institution.

Sera from colonized patients were collected during a prospective study conducted by one of us which received institutional review approval from the local ethical committee.

C. albicans strains. C. albicans serotype A strains consisted of our laboratory reference strain VW32 and BWP17 strain, which was derived from SC5314, the C. albicans strain used for sequencing the whole genome. The serotype B strain consisted of NIH B-792. We included a bmt6Δ strain, which was constructed from BWP17 by deletion of both alleles for the BMT6 gene encoding the mannosyltransferase responsible for the addition of the third β-1,2 linked mannose to PLM21.

Western blotting. Strains were grown in YPD medium (1% yeast extract, 2% peptone, 2% dextrose) at 37 °C for 16 h and were extracted using alkaline extraction under reducing conditions. Briefly, cells were incubated on ice in 1.85 M NaOH and 5% β-mercaptoethanol. Proteins and glycoconjugates were then extracted in SDS for 5 min at 100 °C. Extracts were adjusted to the same protein concentration and analyzed by SDS-PAGE on a 5–20% acrylamide gel slab. Membranes were probed with MAbs B6.1 diluted 1:1000, CA1 diluted 1:1000, and 5B2 diluted 1:1000, and then incubated with a 1:1000 dilution of AP-conjugated anti-mouse IgM (B6.1), or anti-rat IgM (CA1 and 5B2).

Mannan extraction from C. albicans. Mannan was prepared from C. albicans VW32 grown in bioreactors under standard conditions used for the chemical and immunochemical analysis of this molecule. Quantification of mannan was performed by the sulfuric phenol colorimetric method with a range of standard sucrose solutions. Optical density was measured at 492/620 nm.

Detection of human antibodies against C. albicans mannan. Antibodies to C. albicans mannan were detected using the commercially available Platelia Candida Ab kit (Bio-Rad, France). The antigen used to coat the ELISA plates is cell wall mannan extracted from C. albicans serotype A, strain VW32 (see above), extracted by the method of Kocourek and Ballou. Detection of antibodies was performed according to manufacturer’s instructions.

Preparation of BSTOs. The synthesis of oligosaccharides and their biotinylation has been described previously, except for mannotriose. The strategy using for the synthesis of biotinylated β (1 → 2) mannotriose is shown in Fig. 7.

Coupling of BSTOs to fluorescent magnetic beads. Polystyrene fluoromagnetic beads were prepared via a four-step procedure as previously described. Briefly, carboxyl functionalized fluoromagnetic beads were first activated with N-hydroxysulfosuccinimide and ethylcarbodiimide (Pierce Chemicals Co. Rockford, Ill, USA) to form activated esters. After washing in 50 mM phosphate buffered saline (PBS), pH 7.4, these esters were incubated with avidin (Sigma, Saint Quentin Fallavier, France) for 3 h RT. The beads are then blocked with 50 mM PBS containing 250 mM NH4OH for 30 min. After wash in PBS, the beads were coupled with BSTO for 1 h RT and then incubated overnight with 50 mM PBS containing 10% bovine serum albumin. After washing in PBS, the beads were kept at 4°C.

| Probes | Analytical method | References |
|--------|-------------------|------------|
|        | Multiple analysis profiling | Surface plasmon resonance | Western blotting |
| Monoclonal antibodies | X | X | X | |
| SB2    | X | X | X | 35 |
| EB-CA1 | X | X | X | 36 |
| B6.1   | X | X | X | 35 |
| EB-A2  | X | X | X | 36 |
| Human polyclonal antibodies | Polyclonal antibodies from healthy individuals | X | 35, 48, 61 |
| Polyclonal antibodies from colonized patients | X |
| Polyclonal antibodies from infected patients | X |
| Mannose binding lectin | X |

Table 2. Information about antibodies/probes used in the study and technology involved in their analysis.
Quality control of BSTO coupling. For each set of experiments and after coupling BSTOs to magnetic beads, the reactivity of the BSTOs was controlled with a dilution range (1:2000–1:32,000) of biotinylated Galanthus nivalis lectin reacting with α-(1,3)-mannose residues or with a panel of polyclonal and monoclonal antibodies followed by detection with streptavidin–phycoerythrin (2 µg/mL). Mixed suspensions of microspheres coated with different BSTOs were incubated with PBS diluted antibodies for 30 min at 37 °C under agitation. After three washes in PBS-1% Tween 20 (PBST) the microspheres were incubated with appropriate anti-immunoglobulins coupled to phycoerythrin (Southern Biotech, USA).

MAP analysis of BSTO reactivity with sera from patients with invasive candidiasis, ICU colonized patients and controls. Sera were diluted 1:4800 in PBS and incubated for 30 min at 37 °C. After three washes in PBST, the microspheres were incubated with goat anti-human IgG coupled with phycoerythrin (1 µg/mL) (Southern Biotech, USA).

For both procedures, after three washes in PBST the microspheres were re-suspended in sheath fluid in a test tube and the reaction was monitored on a Luminex Lab MAP system 100 (Luminex USA) at 532 nm. The results are expressed as mean fluorescence intensity determined for 100 microspheres of each BSTO identified by its microsphere spectral signature. For human sera, the results were then treated with the “ETALONNAGE” software (University of Lille) and converted into arbitrary units (AU) from calibration curves. Pooled human serum was used as the control standard.

SPR analysis of BSTO reactivity with anti-carbohydrate MAb. BLAcore 3000 instrument, BLAevaluation software 3.0, and sensor chip SA (streptavidin) were obtained from BLAcore (GE Healthcare). 5 nM of BSTOs were fixed onto the sensorchip in HBS (HEPES buffered saline) buffer according to the manufacturer’s instructions using NHS/EDC. The immobilization rate was approximately 25–30 response units (RU). 5B2, EB-CA1, B6.1 and EB-A2 MABs were injected at 250 nM in HBS to 30 µL/min over a 2 min period. The regeneration of sensorship was performed with a 250 mM NaCl/10 mM NaOH buffer. A reference flow cell (i.e. flow cell without BSTOs) was used for each used BSTOs. Quantification of specific binding was obtained from the difference between the ligand and reference response as previously described10.

SPR analysis of BSTO-MBL interactions. With the aim of avoiding non-specific binding induced by non-carbohydrate structures, non-biotinylated oligomannosides were used. rMBL was immobilized onto a CM5
sensorchip (GE Healthcare) in HBS-EP 1X buffer to reach 4000 RU. BSTOs at different concentrations (0, 0.25, 0.5, 1, and 2 mg/mL) were diluted in running buffer composed of HBS-P, CaCl₂ 5 mM, and surfactant 0.05% and injected in BIACore 3000 instrument with a flow at 20 µL/min during 4 min. The sensorchip was regenerated with 0.25 M EDTA buffer. For each sample, the results are expressed as the difference between the tested flow cell and reference flow cell (flow cell without immobilized MBL) as previously described. Normalization of results was performed according to the molecular mass of each BSTO.

Statistical analysis. All statistical analyses were performed using SAS and Med Calc software. Spearman correlation coefficients were calculated to determine the relationship between the reactivity of sera against mannans from *C. albicans* and different BSTOs. The Mann–Whitney U test was used for comparison of antibody levels between different patient groups.

Received: 20 April 2020; Accepted: 10 May 2021
Published online: 24 May 2021

References

1. Axford, J. The impact of glycobiology on medicine. *Trends Immunol.* 22, 237–239 (2001).
2. Kappler, K. & Hennet, T. Emergence and significance of carbohydrate-specific antibodies. *Genes Immun.* 21, 224–239 (2020).
3. Azurmendi, H. F. et al. Chemical structure and genetic organization of the *E. coli* O6K15 capsular polysaccharide. *Sci. Rep.* 10, 12608 (2020).
4. Friedin, C. et al. Beta-1,2 oligomannose adhesin epitopes are widely distributed over the different families of *Candida albicans* cell wall mannproteins and are associated through both N- and O-glycosylation processes. *Infect. Immun.* 76, 4509–4517 (2008).
5. Gow, N. A. R., van de Veerdonk, F. L., Brown, A. J. P. & Netea, M. G. *Candida albicans* morphogenesis and host defence: discriminating invasion from colonization. *Nat. Rev. Microbiol.* 10, 112–122 (2012).
6. Netea, M. G., Joosten, L. A. B., van der Meer, J. W. M., Kullberg, B.-J. & van de Veerdonk, F. L. Immune defence against *Candida* fungal infections. *Nat. Rev. Immunol.* 15, 630–642 (2015).
7. Sendid, B. et al. Antibodies against glucan, chitin, and *Saccharomyces cerevisiae* mannans as new biomarkers of *Candida albicans* infection that complement tests based on *C. albicans* mannans. *Clin. Vaccine Immunol.* 15, 1868–1877 (2008).
8. Collot, M., Wilson, I. B. H., Bublin, M., Hoffmann-Sommergruber, K. & Mallet, J.-M. Synthesis of cross-reactive carbohydrate determinants fragments as tools for in vitro allergy diagnosis. *Biorg. Med. Chem.* 19, 1306–1320 (2011).
9. Kobayashi, H. et al. Identification of the antigenic determinants of factors 8, 9, and 34 of genus Candida. *FEBS Lett.* 395, 109–112 (1996).
10. Collot, M. et al. Biotin sulfol as a new tool for synthetic oligosaccharide immobilization: application to multiple analysis profiling and surface plasmon anlysis of anti- *Candida albicans* antibody reactivity against α and β (1→2) oligomannosides. *J. Med. Chem.* 51, 6201–6210 (2008).
11. Sheriff, S., Chang, C. Y. & Ezekowitz, R. A. B. Human mannose-binding protein carbohydrate recognition domain trimerizes through a triple α-helical coiled-coil. *Nat. Struct. Biol.* 1, 6 (1994).
12. Damiens, S. et al. Characterization of the recognition of *Candida* species by mannose-binding lectin using surface plasmon resonance. *Analyst* 138, 2477–2482 (2013).
13. Yokota, Y., Arai, T. & Kawasaki, T. Oligomeric structures required for complement activation of serum mannann-binding proteins 1. *J. Biochem.* 117, 414–419 (1995).
14. Choteau, L. et al. Role of mannose-binding lectin in intestinal homeostasis and fungal elimination. *Mucosal Immunol.* 9, 767 (2016).
15. Wei, W. I. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. *Nature* 360, 8 (1992).
16. Lillergard, J. B., Sim, R. B., Thorkildson, P., Gates, M. A. & Kozel, T. R. Recognition of *Candida albicans* in vitro and in vivo. *J. Infect. Dis.* 193, 1589–1597 (2006).
17. Courjol, F. et al. β-1,2-Mannosyltransferases 1 and 3 participate in yeast and hyphae O- and N-linked mannosylation and alter *Candida albicans* fitness during infection. *Open Forum Infect. Dis.* 2, 116 (2015).
18. Trinel, P.-A. et al. *Candida albicans* phospholipomannan, a new member of the fungal mannose moisotol phosphoceramide family. *J. Biol. Chem.* 277, 37260–37271 (2002).
19. Trinel, P.-A., Lepage, G., Jouault, T., Streeker, G. & Pouilain, D., Definitive chemical evidence for the constitutive ability of *Candida albicans* serotype A strains to synthesize β-1,2 linked oligomannosides containing up to 14 mannose residues. *FEBS Lett.* 416, 203–206 (1997).
20. Trinel, P.-A. et al. *Candida albicans* serotype B strains synthesize a serotype-specific phospholipomannan overexpressing a β-1,2-linked mannotriose. *Mol. Microbiol.* 58, 984–998 (2005).
21. Millec, C. et al. Members 5 and 6 of the *Candida albicans* BMT family encode enzymes acting specifically on β-mannosylation of the phospholipomannan cell-wall glycoporpholinid. *Glycobiology* 22, 1332–1342 (2012).
22. Pouilain, D., *Candida albicans*, plasticity and pathogenesis. *Crit. Rev. Microbiol.* 41, 208–237 (2015).
23. Domer, J. E. & Garner, R. E. Immunomodulation in response to *Candida*. *Immunol. Ser.* 47, 293–317 (1989).
24. Wang, Y., Li, S. P., Moser, S. A., Bost, K. L. & Domer, J. E. Cytokine involvement in immunomodulatory activity affected by *Candida albicans* mannan. *Infect. Immun.* 66, 1384–1391 (1998).
25. Gow, N. A. R., Latge, J.-P. & Munro, C. A. The fungal cell wall: Structure, biosynthesis, and function. *Microbiol. Spectr.* 5, 1–25 (2017).
26. Goz, S. Immunochemoic study of the mannan of genus *Candida*. I. Structural investigation of antigenic factors 1, 4, 5, 6, 8, 9, 11, 13, 13b and 34. *Curr. Top. Med. Mycol.* 35, 57–70 (1997).
27. Shibata, N., Kobayashi, H. & Suzuki, S. Immunochemistry of pathogenic yeast, *Candida* species, focusing on mannan. *Proc. Ipn. Acad. Ser. B Phys. Biol. Sci.* 88, 250–265 (2012).
28. Kullberg, B. J. & Arendrup, M. C. Invasive Candidiasis. *N. Engl. J. Med.* 373, 1445–1456 (2015).
29. Jouault, T., Delaunoy, C., Sendid, B., Ajana, F. & Pouilain, D. Differential humoral response against alpha- and beta-linked mannose residues associated with tissue invasion by *Candida albicans* residues associated with tissue invasion by *Candida albicans*. *Clin. Transl. Immunol.* 4, 328–333 (1997).
30. Bruno, M. et al. Transcriptional and functional insights into the host immune response against the emerging fungal pathogen *Candida auris*. *Nat. Microbiol.* https://doi.org/10.1038/s41564-020-0780-3 (2020).
31. Fukazawa, Y. Antigenic structure of *Candida albicans*. *Biochem. Biophys. Res. Commun.* 181, 1251–1258 (1991).
33. Faille, C., Wierszecki, J. M., Michalski, J. C., Poulain, D. & Strecker, G. Complete 1H- and 13C-resonance assignments for D-mannooligosaccharides of the beta-D-(1→2)-linked series released from the phosphopeptidomannan of Candida albicans VW32 (serotype A). *Carbohydr. Res.* **236**, 17–27 (1992).

34. Trinel, P. A., Faille, C., Jacquinot, P. M., Cailléz, J. C. & Poulain, D. Mapping of Candida albicans oligomannosidic epitopes by using monoclonal antibodies. *Infect. Immun.* **60**, 3845–3851 (1992).

35. Han, Y., Kanbe, T., Cherniak, R. & Cutler, J. E. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. *Infect. Immun.* **65**, 4100–4107 (1997).

36. Jacquinot, P. M., Plancke, Y., Sendid, B., Strecker, G. & Poulain, D. Nature of Candida albicans-derived carbohydrate antigen recognized by a monoclonal antibody in patient sera and distribution over Candida species. *FEMS Microbiol. Lett.* **169**, 131–138 (1998).

37. Ponton, J. J. et al. Characterization of Candida albicans cell wall antigens with monoclonal antibodies. *Infect. Immun.* **61**, 4842–4847 (1993).

38. Poulain, D. et al. Clearances of Candida albicans-derived alpha- and beta-linked mannose residues in sera from patients with candidiasis. *Eur. J. Clin. Microbiol. Infect. Dis.* **16**, 16–20 (1997).

39. Cutler, J. E., Deepe, G. S. & Klein, B. S. Advances in combating fungal diseases: vaccines on the threshold. *Nat. Rev. Microbiol.* **5**, 13–28 (2007).

40. Han, Y., Riesselman, M. H. & Cutler, J. E. Protection against Candidiasis by an Immunoglobulin G3 (IgG3) Monoclonal Antibody Specific for the Same Mannotriose as an IgM Protective Antibody. *Infect. Immun.* **68**, 1649–1654 (2000).

41. Lipinski, T. et al. A β-mannan trisaccharide conjugate vaccine aids clearance of Candida albicans in immunocompromised rabbits. *Vaccine* **30**, 6263–6269 (2012).

42. Johnson, M. A., Cartmell, J., Weisser, N. E., Woods, R. J. & Bundle, D. R. Molecular recognition of Candida albicans (1→2)-β-mannan oligosaccharides by a protective monoclonal antibody reveals the immunodominance of internal saccharide residues. *J Biol Chem* **287**, 18078–18090 (2012).

43. Gangneux, J.-P. et al. Clinical impact of antifungal susceptibility, biofilm formation and mannose expression of Candida yeasts on the outcome of invasive Candidiasis in ICU: An ancillary study on the prospective AmarCAND2 cohort. *Front. Microbiol.* **9**, 2907 (2018).

44. Jensenius, H. et al. Mannan-binding lectin: Structure, oligomerization, and flexibility studied by atomic force microscopy. *J Mol. Biol.* **391**, 246–259 (2009).

45. Thiel, S. et al. Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: Normal and acute-phase levels in serum and stoichiometry of lectin pathway components: Serum concentrations of MASP-1. *Clin. Exp. Immunol.* **169**, 38–48 (2012).

46. Trinel, P. A., Cantelli, C., Bernigaud, A., Jouault, T. & Poulain, D. Evidence for different mannosylation processes involved in the association of beta-1,2-linked oligomannosidic epitopes in Candida albicans mannan and phospholipomannan. *Microbiology (Reading)* **142**(Pt 8), 2263–2270 (1996).

47. Hopwood, V., Poulain, D., Fortier, B., Evans, G. & Vernes, A. A monoclonal antibody to a cell wall component of Candida albicans. *Infect. Immun.* **54**, 222–227 (1986).

48. Han, Y. & Cutler, J. E. Antibody response that protects against disseminated candidiasis. *Candida albicans* **4842–4847 (1998).**

49. Wilson, R. B., Davis, D. & Mitchell, A. P. Rapid hypothesis testing with candida albicans through gene disruption with short targeted deletions. *Eur. J. Clin. Microbiol. Infect. Dis.* **28**, 9724–9736 (2009).

50. Piarroux, R. et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic candidiasis in critically ill surgical patients. *Crit. Care Med.* **32**, 2443–2449 (2004).

51. Faille, C. et al. Immuno-reactivity of neoglycolipids constructed from oligomannosidic residues of the *Candida albicans* cell wall. *J. Biol. Chem.* **283**, 3537–3544 (1990).

52. Sendid, B. et al. Rapid hypothesis testing with *Pichia pastoris* identification of a new family of genes involved in beta-1,2-mannosylation of glycans in *Candida* and *Saccharomyces* species. *J. Biol. Chem.* **283**, 9724–9736 (2008).

53. Cattiaux, L. et al. Synthetic biotinylated tetra (β1–5) galactofuranoside for in vitro aspergillosis diagnosis. *Bioorg. Med. Chem.* **19**, 547–555 (2011).

54. Sendid, B. et al. New enzyme immunoassays for sensitive detection of circulating *Candida albicans* mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. *J. Clin. Microbiol.* **37**, 1510–1517 (1999).

55. Sendid, B. et al. Combined detection of mannanemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. *J. Med. Microbiol.* **51**, 433–442 (2002).

56. Mikata, Y. et al. Sugar-pendant diamines. *J. Org. Chem.* **66**, 3783–3789 (2001).

Acknowledgements

We thank the European Union for funding through the INTERREG V France—Wallonie—Vlaanderen program—SmartBioControl-BIOSENS project and the Programme Hospitalier de Recherche Clinique, CandiGene, 2011–2018.

Author contributions

S.D., A.-S.D., M.C., K.L., and C.F. performed the experiments. B.S., P.-M.D., D.P., S.D., and C.F. analyzed the data. K.L., B.S., and D.P. interpreted the results of the experiments. E.D., J.de R., S.J., F.G., J.-P.V., J.-M.M., and M.C. contributed by providing reagents/synthetic sugars/analysis tools. B.S., D.P., and J.-M.M. designed the experiments and drafted the manuscript.

Competing interests

The authors declare no competing interests.
